Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Sarah A Lau-Braunhut, MD, Hannah Stone, Griffin Collins, MD, Sigbjørn Berentsen, MD PhD, Matt Zinter, MD, Benjamin Braun, MD PhD

Blood (2019) 134 (Supplement_1): 4798.

https://doi.org/10.1182/blood-2019-126365

Published: 2019

Journal Articles

Serum Complement Levels in Immune Thrombocytopenia: Characterization and Relation to Clinical Features

Abraham Z Cheloff, MS, David J. Kuter, Hanny Al-Samkari, MD

Blood (2019) 134 (Supplement_1): 1087.

https://doi.org/10.1182/blood-2019-125341

Published: 2019

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

Jonathan Weyne, MD, Yan Ni, PhD, Richard DelGizzi, PA, MS, Stephen Godin, PhD, Lori Morton, PhD, Srinivasa Prasad, PhD, Andrew J Rankin, PhD, Melissa Simek-Lemos, MPH, ming-Dauh Wang, PhD, Ronda Rippley, PhD, Olivier Harari, MD PhD

Blood (2018) 132 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2018-99-112262

Published: 2018

Journal Articles

Patient with Myeloma Who Develops Thrombotic Microangiopathy without Hemolysis

Juliana Alvarez Argote, MD

Blood (2018) 132 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2018-99-117095

Published: 2018

Journal Articles

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Claire E McKinley, BSc, Stephen John Richards, PhD FRCPath, Talha Munir, Morag Griffin, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Louise Arnold, Kathryn Riley, Nicola Copeland, Darren J Newton, PhD, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3471.

https://doi.org/10.1182/blood.V130.Suppl_1.3471.3471

Published: 2017

Journal Articles

Final Result of a Pilot Study Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets

Phuong Vo, Enkhtsetseg Purev, MD PhD, Kamille West, Emily McDuffee, Tatyana Worthy, Lisa Cook, Geri Hawks, Brian Wells, Reem Shalabi, Patricia Prince, Tom Hughes, Willy Fleigel, Sharon Adams, MT, CHS (ABHI), Robert Reger, MS, Xin Tian, PhD, Georg Aue, Richard Childs, MD

Blood (2017) 130 (Supplement 1): 1119.

https://doi.org/10.1182/blood.V130.Suppl_1.1119.1119

Published: 2017

Journal Articles

Use of Eculizumab in a Patient with Refractory Autoimmune Hemolytic Anemia with Heterozygous NFκB1 Mutation

Katharine Halligan, MD PhD, Lana Vasiljevic, Phillip Roehrs, MD, Andrew Mcginnitie, MD, Sung-Yun Pai, MD, Rachael F. Grace, MD, Maria Olivares Boucher, MD, Lauren Weintraub, MD

Blood (2017) 130 (Supplement 1): 4743.

https://doi.org/10.1182/blood.V130.Suppl_1.4743.4743

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V Grossi, MDPhD, Pauline Bedwell, Pascal Deschatelets, PhD, Lil Edis, PhD, Cedric G Francois, MDPhD, Patrick J Johnson, PhD, Helen J Richardson, Lisa Tan, Carolina A Vega, Jason Lickliter, MBBS,PhD

Blood (2016) 128 (22): 1251.

https://doi.org/10.1182/blood.V128.22.1251.1251

Published: 2016

Journal Articles

Thrombocytopenia and Microangiopathic Hemolytic Anemia Precipitated By Acute Pancreatitis: A Single Center Experience of Five Cases

Mary Salib, MD, Anne-Sophie Lemay, MD FRCPC, Megan Buchholz, RN, Katerina Pavenski, BSc, MD FRCPC

Blood (2016) 128 (22): 1377.

https://doi.org/10.1182/blood.V128.22.1377.1377

Published: 2016

Journal Articles

Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and I n Vivo Efficacy Results

Dipanjan Pan, PhD, Stephen Rogers, PhD, Santosh Misra, PhD, Gururaja Vulugundam, PhD, Lisa Gazdzinski, MS, Albert Tsui, PhD, Nikhil Mistry, MS, Ahmed Said, MD PhD, Philip Spinella, MD, Greg Hare, MD PhD, Greg Lanza, MD PhD, Allan Doctor, MD

Blood (2016) 128 (22): 1027.

https://doi.org/10.1182/blood.V128.22.1027.1027

Published: 2016

Journal Articles

Eculizumab Therapy of Adult TA-TMA: A High Response Rate Is Associated with a High Infection-Related Mortality

Stephan R Bohl, Stephanie Harsdorf, Stefan Schoensteiner, Phyllis Schwarzwaelder, Katrina Scholl, Verena Wais, Lars Bullinger, MD, Hartmut Döhner, MD, Florian Kuchenbauer, Donald Bunjes

Blood (2016) 128 (22): 2255.

https://doi.org/10.1182/blood.V128.22.2255.2255

Published: 2016

Journal Articles

Aplastic Anemia in the Context of Hemolytic Paroxysmal Nocturnal Hemoglobinuria: Feasibility of Antibody-Based Intensive Immunosuppression during Eculizumab Treatment

Simona Pagliuca, MD, Flore Sicre de Fontbrune, MD, Serena Marotta, MD, Anna Paola Iori, Marie Robin, MD PhD, Gérard Socié, MD PhD, Regis Peffault de Latour, MD PhD, Antonio M Risitano, MD PhD

Blood (2016) 128 (22): 5074.

https://doi.org/10.1182/blood.V128.22.5074.5074

Published: 2016

Journal Articles

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Bernd Jilma, MD, James C Gilbert, MD, Sandip Panicker, PhD, Graham C Parry, PhD, Michael Fillitz, MD, Schenk Thomas, Christian Sillaber, MD, Johann Bartko, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 2435.

https://doi.org/10.1182/blood.V128.22.2435.2435

Published: 2016

Journal Articles

Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets

Phuong T. Vo, MD, Enkhtsetseg Purev, Kamille A West, MD, Michael Hochman, Emily C. McDuffee, PhD DO, Tatyana Worthy, Lisa Cook, Catalina Ramos, Brian Wells, Willy A. Flegel, Sharon Adams, Robert N. Reger, Georg Aue, Richard W. Childs

Blood (2016) 128 (22): 3840.

https://doi.org/10.1182/blood.V128.22.3840.3840

Published: 2016

Journal Articles

Complement Genotype and Multiparametric Laboratory Analysis to Predict Response to Eculizumab and to Adjust Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Marta Subías-Hidalgo, PhD, Alicia Lopez, PhD, Jaouad Anter, PhD, Sheila Pinto, PhD, Emilio Ojeda, MD, Jose A Garcia-Marco, MD PhD, Fernando Ataulfo Gonzalez-Fernandez, MD, Rafael Fores, MD, Laura Llorente, MD, Ana Maria Villegas-Martinez, MD, Santiago Rodriguez-Cordoba, MD

Blood (2015) 126 (23): 2139.

https://doi.org/10.1182/blood.V126.23.2139.2139

Published: 2015

Journal Articles

C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Saskia Langemeijer, MD PhD, Jun-Ichi Nishimura, MD PhD, Wynne Weston-Davies, Miles A Nunn, DPhil, Yuzuru Kanakura, MD PhD, Ian J Mackie, Petra Muus, MD PhD

Blood (2015) 126 (23): 1209.

https://doi.org/10.1182/blood.V126.23.1209.1209

Published: 2015

Journal Articles

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Mark B Pepys, MDPhDFRS FMedSci, Louise M Cookson, BSc, Sharon V Barton, BSc MSc, Alienor C Berges, PharmD, Thirusha Lane, RN MSc, David Hutt, BAppSc, Marianna Fontana, MD, James C Moon, MD, Julian D Gillmore, MDPhDFRCP, Ashutosh Wechalekar, MDFRCPath FRCP, Philip N Hawkins, MDPhDFMedSci, Duncan B Richards, DM FRCP

Blood (2015) 126 (23): 1836.

https://doi.org/10.1182/blood.V126.23.1836.1836

Published: 2015

NARROW

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Serum Complement Levels in Immune Thrombocytopenia: Characterization and Relation to Clinical Features

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of REGN3918, a Human Antibody Against Complement Factor C5, in Healthy Volunteers

Patient with Myeloma Who Develops Thrombotic Microangiopathy without Hemolysis

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Final Result of a Pilot Study Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets

Use of Eculizumab in a Patient with Refractory Autoimmune Hemolytic Anemia with Heterozygous NFκB1 Mutation

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Thrombocytopenia and Microangiopathic Hemolytic Anemia Precipitated By Acute Pancreatitis: A Single Center Experience of Five Cases

Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and I n Vivo Efficacy Results

Eculizumab Therapy of Adult TA-TMA: A High Response Rate Is Associated with a High Infection-Related Mortality

Aplastic Anemia in the Context of Hemolytic Paroxysmal Nocturnal Hemoglobinuria: Feasibility of Antibody-Based Intensive Immunosuppression during Eculizumab Treatment

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets

Complement Genotype and Multiparametric Laboratory Analysis to Predict Response to Eculizumab and to Adjust Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only